Our inherited retinal disease (IRD) research team needs your input to help us identify educational content relating to ocular genetics and gene therapy that would be beneficial for optometrists and ophthalmologists in Australia and New Zealand.
Safety and efficacy of AGN-190584 in individuals with presbyopia: The Gemini 1 phase 3 randomised clinical trialDr George Waring IV et al
Congenital cataract typically presents in infancy with variable lens opacities that block the normal red reflex (Fig 1). It can be associated with other ocular and systemic abnormalities. There may be a family history of cataract and the inherited forms are typically autosomal dominant. Diagnosing t
Myopia is one of the most common eye disorders and its prevalence is increasing worldwide, including in Australia and New Zealand. The condition’s refractive error is due to a mismatch between axial length and the optical power of the eye, with axial myopia’s severity directly related to axial lengt
In March 2022, the breakthrough gene therapy treatment Luxturna was approved for public funding in Australia, two years after the UK did so and four years after it was fast-tracked to become the first FDA-approved gene therapy. Designed for people with vision loss caused by inherited retinal dystrop
With last-minute apologies from the night’s guest speaker, Tauranga-based paediatric and strabismus specialist Dr Cheefoong Chong, and Eye Surgery Associates’ (ESA’s) medical retina and vitreoretinal (VR) surgeon Dr Monika Pradhan presenting on Zoom, ESA’s winter seminar was an example of the new no
We all look at faces and eyes every day. Be it refracting, screening for diabetic retinopathy, looking for retinal tears or monitoring glaucoma, we are looking closely. But do we see? Do we look for and see the nodular basal cell carcinoma at the medial canthus or the squamous cell carcinoma on the
As a hospital-based optometrist, I was very excited to hear of the recent Optometrists and Dispensing Opticians Board’s decision to approve a new scope of practice for hospital-based optometrists in ophthalmic laser surgery and its associated prescribing qualification. This is a major milestone for
Ophthalmic imaging has come a long way in the last 15 years. Optical coherence tomography (OCT) and more recently OCT angiography (OCTA) have become indispensable parts of our clinical patient evaluation, not only for retinal disease but also for uveitis and optic nerve disorders. Mastering the art
Glaucoma prevalence in New Zealand is increasing as our population ages, and the country’s public health system is bursting at the seams with the burden. Over the past two decades, various initiatives have evolved to try and tackle this problem head on, but are they making a difference?
Like many things, the O-Show (originally scheduled for May 2020) followed a circuitous path thanks to the pandemic, eventually taking place from 28-29 May 2022 in Sydney’s Hordern Pavilion. But, boy, was it worth the wait!
Pilot evaluation for an image-based eyelid lesion management service
